title: Pregabalin for decreasing pancreatic pain in chronic pancreatitis.
abstract: BACKGROUND
  Chronic abdominal pain is one of the major symptoms in people with chronic pancreatitis. The role of pregabalin in people with chronic pancreatic pain due to chronic pancreatitis is uncertain.
  
  
  OBJECTIVE
  To assess the benefits and harms of pregabalin in people with chronic abdominal pain due to chronic pancreatitis.
  
  
  METHODS
  We searched the Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library 2015, issue 6, and MEDLINE, EMBASE, Science Citation Index Expanded, trials registers until June 2015. We also searched the references of included trials to identify further trials.
  
  
  METHODS
  We considered only randomised controlled trials (RCT) performed in people with chronic pancreatic pain due to chronic pancreatitis, irrespective of language, blinding, or publication status for inclusion in the review.
  
  
  METHODS
  Two review authors independently identified trials and independently extracted data. We calculated the risk ratio (RR) or mean difference (MD) with 95% confidence intervals (CI) with RevMan 5, based on intention-to-treat analysis.
  
  
  RESULTS
  Only one study, funded by Pfizer, met the inclusion criteria for the review. A total of 64 participants (with chronic pain due to chronic pancreatitis) were randomly assigned to receive escalating doses of pregabalin (150 mg per day to 600 mg per day; 34 participants) or matching placebo (30 participants). Participants received pregabalin or placebo for three weeks on an outpatient basis; the outcomes were measured at the end of the treatment (i.e. three weeks from commencement of treatment). Potential participants taking concomitant analgesic medication and expected to stay on a stable regime during the trial were allowed to enter the study. This trial was at low risk of bias. The overall quality of evidence was low or moderate.Only the short-term outcomes were available in this trial. The medium and long-term outcomes, number of work days lost, and length of hospital stay due to admissions for pain control were not available. This trial found that the changes in opiate use (MD -26.00 mg; 95% CI -47.36 to -4.64; participants = 64; moderate-quality evidence), and pain score percentage changes from baseline (MD -12.00; 95% CI -21.82 to -2.18; participants = 64; moderate-quality evidence) were better in participants taking pregabalin compared to those taking placebo. This trial also found that there were more adverse events in participants taking pregabalin compared to those taking placebo (RR 1.71; 95% CI 1.20 to 2.43; participants = 64). The differences between pregabalin and placebo were imprecise for short-term health-related quality of life measured with the EORTC CLQ-30 questionnaire (MD 11.40; 95% CI -3.28 to 26.08; participants = 64; moderate-quality evidence), proportion of people with serious adverse events (RR 1.76; 95% CI 0.35 to 8.96; participants = 64; low-quality evidence), and proportion of people requiring hospital admissions (RR 0.44; 95% CI 0.04 to 4.62; participants = 64; low quality evidence).
  
  
  CONCLUSIONS
  Based on low- to moderate-quality evidence, short-term use of pregabalin decreases short-term opiate use, and short-term pain scores, but increases the adverse events compared to placebo, in people with chronic pain due to chronic pancreatitis. The clinical implication of the decreases in short-term opiate use and short-term pain scores is not known.Future trials assessing the role of pregabalin in decreasing chronic pain in chronic pancreatitis should assess the medium- or long-term effects of pregabalin and should include outcomes such as, quality of life, treatment-related adverse events, number of work days lost, number of hospital admissions, and the length of hospital stay, in addition to pain scores, to assess the clinical and socioeconomic impact.
authors.affiliation: Department of Surgery, Royal Free Campus, UCL Medical School, Royal Free Hospital, Rowland Hill Street, London, UK, NW3 2PF.
authors.forename: Kurinchi Selvan
authors.initials: KS
authors.lastname: Gurusamy
authors.forename: Charnelle
authors.initials: C
authors.lastname: Lusuku
authors.forename: Brian R
authors.initials: BR
authors.lastname: Davidson
mesh_terms: D000700:Analgesics / Q000627:therapeutic use*; D059350:Chronic Pain / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D010182:Pancreatic Diseases / Q000188:drug therapy* / Q000209:etiology; D050500:Pancreatitis, Chronic / Q000150:complications*; D000069583:Pregabalin / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic
chemical_list: D000700:Analgesics; D000069583:Pregabalin
references.citation: Gastroenterology. 2011 Aug;141(2):536-43
references.pmid: 21683078
references.citation: BMC Gastroenterol. 2013 Mar 18;13:49
references.pmid: 23506415
references.citation: J Gastroenterol. 2010 Jun;45(6):584-91
references.pmid: 20422433
references.citation: PLoS One. 2012;7(8):e42096
references.pmid: 22879908
references.citation: Rev Esp Enferm Dig. 2014 Apr;106(4):239-45
references.pmid: 25075654
references.citation: BMC Gastroenterol. 2009 Dec 14;9:93
references.pmid: 20003450
references.citation: Eur J Gastroenterol Hepatol. 2001 Jun;13(6):749-50
references.pmid: 11434607
references.citation: PLoS One. 2013;8(3):e57963
references.pmid: 23469256
references.citation: Pancreas. 1997 Apr;14(3):215-21
references.pmid: 9094150
references.citation: J Gastroenterol. 2007 Feb;42(2):101-19
references.pmid: 17351799
references.citation: World J Gastroenterol. 2013 May 28;19(20):3018-26
references.pmid: 23716981
references.citation: Control Clin Trials. 1986 Sep;7(3):177-88
references.pmid: 3802833
references.citation: Curr Opin Pharmacol. 2006 Feb;6(1):108-13
references.pmid: 16376147
references.citation: Stat Med. 1987 Apr-May;6(3):341-50
references.pmid: 3616287
references.citation: Br J Clin Pharmacol. 2012 Mar;73(3):363-72
references.pmid: 21950372
references.citation: Aliment Pharmacol Ther. 2011 Oct;34(8):878-87
references.pmid: 21848870
references.citation: BMJ. 1997 Sep 13;315(7109):629-34
references.pmid: 9310563
references.citation: Anesth Analg. 2007 Dec;105(6):1805-15
references.pmid: 18042886
references.citation: Am J Gastroenterol. 2011 Dec;106(12):2192-9
references.pmid: 21946280
references.citation: JOP. 2006 Jul 10;7(4):390-6
references.pmid: 16832136
references.citation: J Eval Clin Pract. 2014 Jun;20(3):203-7
references.pmid: 24661411
references.citation: Pain Res Manag. 2014 Nov-Dec;19(6):e164-7
references.pmid: 24945288
references.citation: Stat Med. 1998 Dec 30;17(24):2815-34
references.pmid: 9921604
references.citation: Dig Dis Sci. 2009 Nov;54(11):2330-7
references.pmid: 19137428
references.citation: World J Surg. 2003 Nov;27(11):1241-8
references.pmid: 14534823
references.citation: Dig Dis Sci. 2010 Oct;55(10):2988-98
references.pmid: 20108119
references.citation: Lancet. 2011 Apr 2;377(9772):1184-97
references.pmid: 21397320
references.citation: Gastroenterol Clin North Am. 2007 Jun;36(2):335-64, ix
references.pmid: 17533083